GLG Topic: Oncology
Oncology is the field of medicine dealing with tumors (cancer), including their biology, prevention, diagnosis, and treatment. Cancer biology focuses on the mechanisms for abnormal cell growth and tumor metastasis; diagnosis involves biopsy, endoscopy, radiological imaging, nuclear medicine, and blood tests for tumor markers; prevention includes genetic testing, education, and screening; therapies like surgery, chemotherapy, and radiation therapy aim to inhibit tumor development.
Request a consultation
Leading Experts: Oncology
 |
What is a GLG Leader? |
Donald Fleming, MDDivision Head of Hematology and Oncology
MEDICAL CENTER OF VINCENNES
Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...
Radiation Oncologist
St. Vincent's Comprehensive Cancer Center
Lawrence Tena, MD, is an Attending Physician in the Department of Radiation Oncology at St. Vincent's Comprehensive Cancer Center in New York. He is also an Assistant Professor of Radiation Oncology at the New York Medical College and an Associate Adjunct at the New York Eye and Ear Infirmary. Dr. Tena...
Professor
UNIVERSITY OF ALABAMA AT BIRMINGHAM
Alfred Bartolucci, PhD, is a Professor of Biostatistics at University of Alabama at Birmingham. Dr. Bartolucci’s areas of expertise in applied statistics are oncology (particularly prostate and breast cancer), Alzheimer's disease, cardiovascular disease, statistical genetic association research, and...
Kenneth Algazy, MDClinical Professor of Medicine
University of Pennsylvania School of Medicine - CC
Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School
Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.
Study Groups: Oncology(?)
GLG NewsSM
Analysis: Oncology(?)
Lilly will likely get front line approval for Alimta in non small cell lung cancer Most patients with advanced disease never see a response to therapy
Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight
Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE
ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors
The failure of this study has wide ranging implications for Pfizer and other melanoma trials. This drug, which only a few years ago caused much excitement in the melanoma oncology community, failed to show any survival benefit in this Phase III trial, when compared to standard, but generally ineffective,...
GLG InstituteSM
Seminars: Oncology(?)
View All View all GLG InstituteSM Seminars in in HealthcareQuick Facts about GLG
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms